Pharmacological actions of multi-target-directed evodiamine

Molecules

Volumn 18, Issue 2, 2013, Pages 1826-1843

  Yu, Hui ^a,b   Jin, Hongwei ^c   Gong, Wuzhuang ^b   Wang, Zhanli ^b   Liang, Huaping ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b BAOTOU MEDICAL COLLEGE   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Bioactivity; Evodiamine; Mechanism; Receptor binding

Indexed keywords

EVODIAMINE; LIGAND; PROTEIN; QUINAZOLINE DERIVATIVE;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; REVIEW;

ANIMALS; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEINS; QUINAZOLINES;

MLCS; MLOWN;

EID: 84874609274     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18021826     Document Type: Review

References (136)

1. Wang, Y.; Fan, X.; Qu, H.; Gao, X.; Cheng, Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional chinese medicine. Curr. Top Med. Chem. 2012, 12, 1356-1362.
2. Petrelli, A.; Giordano, S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr. Med. Chem. 2008, 15, 422-432. (Pubitemid 351472408)
3. Tong, X.L.; Dong, L.; Chen, L.; Zhen, Z. Treatment of diabetes using traditional Chinese medicine: Past, present and future. Am. J. Chin. Med. 2012, 40, 877-886.
4. Wang, S.; Wu, X.; Tan, M.; Gong, J.; Tan, W.; Bian, B.; Chen, M.; Wang, Y. Fighting fire with fire: Poisonous Chinese herbal medicine for cancer therapy. J. Ethnopharmacol. 2012, 140, 33-45.
5. Chen, Y.F. Traditional Chinese herbal medicine and cerebral ischemia. Front Biosci. (Elite Ed.) 2012, 4, 809-817.
6. Liu, Z.L.; Liu, J.P.; Zhang, A.L.; Wu, Q.; Ruan, Y.; Lewith, G.; Visconte, D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst. Rev. 2011, 7, CD008305.
7. Yue, R.; Shan, L.; Yang, X.; Zhang, W. Approaches to target profiling of natural products. Curr. Med. Chem. 2012, 19, 3841-3855.
8. Zhao, J.; Yang, P.; Li, F.; Tao, L.; Ding, H.; Rui, Y.; Cao, Z.; Zhang, W. Therapeutic effects of astragaloside IV on myocardial injuries: Multi-target identification and network analysis. PLoS One 2012, 7, e44938.
9. Liao, J.F.; Chiou, W.F.; Shen, Y.C.; Wang, G.J.; Chen, C.F. Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components. Chin. Med. 2011, 6, 6-13.
10. Moon, T.C.; Murakami, M.; Kudo, I.; Son, K.H.; Kim, H.P.; Kang, S.S.; Chang, H.W. A new class of COX-2 inhibitor, rutaecarpine from Evodia rutaecarpa. Inflamm. Res. 1999, 48, 621-625. (Pubitemid 30017099)
11. Choi, Y.H.; Shin, E.M.; Kim, Y.S.; Cai, X.F.; Lee, J.J.; Kim, H.P. Anti-inflammatory principles from the fruits of Evodia rutaecarpa and their cellular action mechanisms. Arch. Pharm. Res. 2006, 29, 293-297.
12. Kobayashi, Y.; Nakano, Y.; Kizaki, M.; Hoshikuma, K.; Yokoo, Y.; Kamiya, T. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med. 2001, 67, 628-633. (Pubitemid 32929573)
13. Fei, X.F.; Wang, B.X.; Li, T.J.; Tashiro, S.; Minami, M.; Xing, D.J.; Ikejima, T. Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci. 2003, 94, 92-98. (Pubitemid 36575865)
14. Kobayashi, Y. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 2003, 69, 425-428. (Pubitemid 36774182)
15. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992, 6, 3051-3064.
16. Chiou, W.F.; Sung, Y.J.; Liao, J.F.; Shum, A.Y.; Chen, C.F. Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J. Nat. Prod. 1997, 60, 708-711. (Pubitemid 27318419)
17. Ko, H.C.; Wang, Y.H.; Liou, K.T.; Chen, C.M.; Chen, C.H.; Wang, W.Y.; Chang, S.; Hou, Y.C.; Chen, K.T.; Chen, C.F.; et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur. J. Pharmacol. 2007, 555, 211-217. (Pubitemid 46048800)
18. Liu, Y.N.; Pan, S.L.; Liao, C.H.; Huang, D.Y.; Guh, J.H.; Peng, C.Y.; Chang, Y.L.; Teng, C.M. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock 2009, 32, 263-269.
19. Lin, C.R.; Amaya, F.; Barrett, L.; Wang, H.; Takada, J.; Samad, T.A.; Woolf, C.J. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J. Pharmacol. Exp. Ther. 2006, 319, 1096-1103.
20. Ogasawara, M.; Matsubara, T.; Suzuki, H. Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol. Pharm. Bull. 2001, 24, 917-920. (Pubitemid 32750318)
21. Ogasawara, M.; Matsubara, T.; Takahashi, S.; Saiki, I.; Suzuki, H. Anti-invasive and metastatic activities of evodiamine. Biol. Pharm. Bull. 2002, 25, 1491-1493. (Pubitemid 39663174)
22. Wang, C.; Wang, M.W.; Tashiro, S.; Onodera, S.; Ikejima, T. Evodiamine induced human melanoma A375-S2 cell death partially through interleukin 1 mediated pathway. Biol. Pharm. Bull. 2005, 28, 984-989. (Pubitemid 40880301)
23. Lee, T.J.; Kim, E.J.; Kim, S.; Jung, E.M.; Park, J.W.; Jeong, S.H.; Park, S.E.; Yoo, Y.H.; Kwon, T.K. Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Mol. Cancer Ther. 2006, 5, 2398-2407. (Pubitemid 44530477)
24. Huang, Y.C.; Guh, J.H.; Teng, C.M. Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci. 2004, 75, 35-49.
25. Kan, S.F.; Yu, C.H.; Pu, H.F.; Hsu, J.M.; Chen, M.J.; Wang, P.S. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J. Cell. Biochem. 2007, 101, 44-56. (Pubitemid 46652571)
26. Huang, D.M.; Guh, J.H.; Huang, Y.T.; Chueh, S.C.; Chiang, P.C.; Teng, C.M. Induction of mitotic arrest and apoptosis in human prostate cancer PC-3 cells by evodiamine. J. Urol. 2005, 173, 256-261.
27. Kang, S.F.; Huang, W.J.; Lin, L.C.; Wang, P.S. Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int. J. Cancer 2004, 110, 641-651. (Pubitemid 38746021)
28. Liao, C.H.; Pan, S.L.; Guh, J.H.; Chang, Y.L.; Pai, H.C.; Lin, C.H.; Teng, C.M. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 2005, 26, 968-975.
29. Jiang, J.; Hu, C. Evodiamine: A novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 2009, 14, 1852-1859.
30. Zhang. Y.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikejima, T. Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol. Pharm. Bull. 2003, 26, 1543-1547. (Pubitemid 41699632)
31. Zhang. Y.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikejima, T. Evodiamine induces tumor cell death through two different pathways: Apoptosis and necrosis. Acta Pharmacol. Sin. 2004, 25, 83-89. (Pubitemid 38076083)
32. Zhang, Y.; Zhang, Q.H.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikejima, T. A typical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J. Asian Nat. Prod. Res. 2004, 6, 19-27. (Pubitemid 38190218)
33. Takada, Y.; Kobayashi, Y.; Aggarwal, B.B. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 2005, 280, 17203-17212. (Pubitemid 41389187)
34. Chen, M.C.; Yu, C.H.; Wang, S.W.; Pu, H.F.; Kan, S.F.; Lin, L.C.; Chi, C.W.; Ho, L.L.; Lee, C.H.; Wang, P.S. Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J. Cell. Biochem. 2010, 110, 1495-1503.
35. Zhang, C.; Fan, X.; Xu, X.; Yang, X.; Wang, X.; Liang, H.P. Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells. Anticancer Drugs 2010, 21, 766-776.
36. Yang, J.; Wu, L.J.; Tashino, S.; Onodera, S.; Ikejima, T. Critical roles of reactive oxygen species in mitochondrial permeability transition in mediating evodiamine-induced human melanoma A375-S2 cell apoptosis. Free Radic. Res. 2007, 41, 1099-1108. (Pubitemid 47470847)
37. Yang, J.; Wu, L.J.; Tashiro, S.; Onodera, S.; Ikejima, T. Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells. Free Radic. Res. 2008, 42, 1-11. (Pubitemid 351372186)
38. Yang, J.; Wu, L.J.; Tashino, S.; Onodera, S.; Ikejima, T. Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic. Res. 2008, 42, 492-504. (Pubitemid 351935163)
39. Yang, J.; Wu, L.J.; Tashino, S.; Onodera, S.; Ikejima, T. Protein tyrosine kinase pathway-derived ROS/NO productions contribute to G2/M cell cycle arrest in evodiamine-treated human cervix carcinoma Hela cells. Free Radic. Res. 2010, 44, 792-802.
40. Wang, C.; Li, S.; Wang, M.W. Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol. In Vitro 2010, 24, 898-904.
41. Wei, W.T.; Chen, H.; Wang, Z.H.; Ni, Z.L.; Liu, H.B.; Tong, H.F.; Guo, H.C.; Liu, D.L.; Lin, S.Z. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int. J. Biol. Sci. 2012, 8, 1-14.
42. Chao, D.C.; Lin, L.J.; Hsiang, C.Y.; Li, C.C.; Lo, H.Y.; Liang, J.A.; Kao, S.T.; Wu, S.L.; Ho, T.Y. Evodiamine inhibits 12-O-tetradecanoylphorbol-13- acetate-induced activator protein 1 transactivation and cell transformation in human hepatocytes. Phytother. Res. 2011, 25, 1018-1023.
43. Shyu, K.G.; Lin, S.; Lee, C.C.; Chen, E.; Lin, L.C.; Wang, B.W.; Tsai, S.C. Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci. 2006, 78, 2234-2243.
44. Ogasawara, M.; Suzuki, H. Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells. Biol. Pharm. Bull. 2004, 27, 578-582. (Pubitemid 41701850)
45. Pan, X.; Hartley, J.M.; Hartley, J.A.; White, K.N.; Wang, Z.; Bligh, S.W. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 2012, 19, 618-624.
46. Chan, A.L.; Chang, W.S.; Chen, L.M.; Lee, C.M.; Chen, C.E.; Lin, C.M.; Hwang, J.L. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules 2009, 14, 1342-1352.
47. Sheng, C.; Miao, Z.; Zhang, W. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors. Curr. Med. Chem. 2011, 18, 4389-4409.
48. Dong, G.; Sheng, C.; Wang, S.; Miao, Z.; Yao, J.; Zhang, W. Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J. Med. Chem. 2010, 53, 7521-7531.
49. Hu, Y.; Fahmy, H.; Zjawiony, J.K.; Davies, G.E. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia 2010, 81, 259-268.
50. Shi, J.; Yan, J.; Lei, Q.; Zhao, J.; Chen, K.; Yang, D.; Zhao, X.; Zhang, Y. Intragastric administration of evodiamine suppresses NPY and AgRP gene expression in the hypothalamus and decreases food intake in rats. Brain Res. 2009, 1247, 71-78.
51. Wang, T.; Wang, Y.; Yamashita, H. Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway. FEBS Lett. 2009, 583, 3655-3659.
52. Wang, T.; Wang, Y.; Kontani, Y.; Kobayashi, Y.; Sato, Y.; Mori, N.; Yamashita, H. Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: Involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling. Endocrinology 2008, 149, 358-366.
53. Wu, C.L.; Hung, C.R.; Chang, F.Y.; Lin, L.C.; Pau, K.Y.; Wang, P.S. Effects of evodiamine on gastrointestinal motility in male rats. Eur. J. Pharmacol. 2002, 457, 169-176. (Pubitemid 35447659)
54. Vincent, R.P.; Ashrafian, H.; le Roux, C.W. Mechanisms of disease: The role of gastrointestinal hormones in appetite and obesity. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5, 268-277. (Pubitemid 351637912)
55. Yang, H.Y.; Li, S.Y.; Chen, C.F. Hypotensive effects of dehydroevodiamine, a quinazolinocarboline alkaloid isolated from Evodia rutaecarpa. Asia Pac. J. Pharmacol. 1988, 3, 191-195.
56. Yang, M.C.; Wu, S.L.; Kao, J.S.; Chen, C.F. The hypotensive and negative chronotropic effect of dehydroevodiamine. Eur. J. Pharmacol. 1990, 182, 537-542. (Pubitemid 20260773)
57. Chiou, W.F.; Chou, C.J.; Shum, A.Y.C.; Chen, C.F. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: Mode of action. Eur. J. Pharmacol. 1992, 215, 277-283.
58. Chiou, W.F.; Liao, J.F.; Chen, C.F. Comparative study on vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J. Nat. Prod. 1996, 59, 374-378.
59. Chen, C.F.; Chen, S.M.; Lin, M.T.; Chow, S.Y. In vivo and in vitro studies on the mechanism of cardiovascular effects of Wu-Chu-Yu (Evodiae fructus). Am. J. Chin. Med. 1981, 9, 39-47. (Pubitemid 12190231)
60. Hung, P.H.; Lin, L.C.; Wang, G.J.; Chen, C.F.; Wang, P.S. Inhibitory effect of evodiamine on aldosterone release by Zona glomerulosa cells in male rats. Chin. J. Physiol. 2001, 44, 53-57. (Pubitemid 32601324)
61. Kobayashi, Y.; Hoshikuma, K.; Nakano, Y.; Yokoo, Y.; Kamiya, T. The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: Possible involvement of vanilloid receptors. Planta Med. 2001, 67, 244-248. (Pubitemid 32304195)
62. Rang, W.Q.; Du, Y.H.; Hu, C.P.; Ye, F.; Tan, G.S.; Deng, H.W.; Li, Y.J. Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 367, 306-311. (Pubitemid 36408013)
63. Yi, H.H.; Rang, W.Q.; Deng, P.Y.; Hu, C.P.; Liu, G.Z.; Tan, G.S.; Xu, K.P.; Li, Y.J. Protective effects of rutaecarpine in cardiac anaphylactic injury is mediated by CGRP. Planta Med. 2004, 70, 1135-1139.
64. Yu, J.; Tan, G.S.; Deng, P.Y.; Xu, K.P.; Hu, C.P.; Li, Y.J. Involvement of CGRP in the inhibitory effect of rutaecarpine on vasoconstriction induced by anaphylaxis in guinea pig. Regul. Pept. 2005, 125, 93-97. (Pubitemid 39593713)
65. Rang, W.Q.; Du, Y.H.; Hu, C.P.; Ye, F.; Xu, K.P.; Peng, J.; Deng, H.W.; Li, Y.J. Protective effects of evodiamine on myocardial ischemia-reperfusion injury in rats. Planta Med. 2004, 70, 1140-1143. (Pubitemid 40101093)
66. Hu, C.P.; Xiao, L.; Deng, H.W.; Li, Y.J. The cardioprotection of rutaecarpine is mediated by endogenous calcitonin release-gene peptide through activation of vanilloid receptors in guinea-pig hearts. Planta Med. 2002, 68, 705-709. (Pubitemid 35013381)
67. Heo, S.K.; Yun, H.J.; Yi, H.S.; Noh, E.K.; Park, S.D. Evodiamine and rutaecarpine inhibit migration by LIGHT via suppression of NADPH oxidase activation. J. Cell. Biochem. 2009, 107, 123-133.
68. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430, 631-639. (Pubitemid 39061671)
69. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356. (Pubitemid 34790756)
70. Kim, H.K.; Kim, M.; Kim, S.; Kim, M.; Chung, J.H. Effects of green tea polyphenol on cognitive and acetylcholinesterase activities. Biosci. Biotechnol. Biochem. 2004, 68, 1977-1979. (Pubitemid 39415267)
71. Lu, J.H.; Guo, J.; Yang, W.H. Effects of green tea polyphenol on the behaviour of Alzheimer's disease like mice induced by D-galactose and Abeta25-35. Zhong Yao Cai 2006, 29, 352-354.
72. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280, 37377-37382. (Pubitemid 41642343)
73. Karuppagounder, S.S.; Pinto, J.T.; Xu, H.; Chen, H.L.; Beal, M.F.; Gibson, G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54, 111-118.
74. Sehirli, O.; Tozan, A.; Omurtag, G.Z.; Cetinel, S.; Contuk, G.; Gedik, N.; Sener, G. Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol. Environ. Saf. 2008, 71, 301-308.
75. Haji, A.; Momose, Y.; Takeda, R.; Nakanishi, S.; Hiriachi, T.; Arisawa, M. Increased feline cerebral blood flow induced by dehydroevodiamine hydrochloride from Evodia rutaecarpa. J. Nat. Prod. 1994, 57, 387-389. (Pubitemid 24123504)
76. Yuan, S.M.; Gao, K.; Wang, D.M.; Quan, X.Z.; Liu, J.N.; Ma, C.M.; Qin, C.; Zhang, L.F. Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease. Acta Pharmacol. Sin. 2011, 32, 295-302.
77. Park, C.H.; Kim, S.H.; Choi, W.; Lee, Y.J.; Kim, J.S.; Kang, S.S.; Suh, Y.H. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med. 1996, 62, 405-409. (Pubitemid 26370329)
78. Perrett, S.; Whitfield, P.J. Atanine (3-dimethylallyl-4-methoxy-2- quinolone), an alkaloid with anthelmintic activity from the Chinese medicinal plant, Evodia rutaecarpa. Planta Med. 1995, 61, 276-278.
79. Rho, T.C.; Bae, E.A.; Kim, D.H.; Oh, W.K.; Kim, B.Y.; Ahn, J.S.; Lee, H.S. Anti-Helicobacter pylori activity of quinolone alkaloids from Evodiae Fructus. Biol. Pharm. Bull. 1999, 22, 1141-1143. (Pubitemid 29507962)
80. Hamasaki, N.; Ishii, E.; Tominaga, K.; Tezuka, Y.; Nagaoka, T.; Kadota, S.; Kuroki, T.; Yano, I. Highly selective antibacterial activity of novel alkyl quinolone alkaloids from a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori in vitro. Microbiol. Immunol. 2000, 44, 9-15. (Pubitemid 30073693)
81. Tominaga, K.; Higuchi, K.; Hamasaki, N.; Hamaguchi, M.; Takashima, T.; Tanigawa, T.; Watanabe, T.; Fujiwara, Y.; Tezuke, Y.; Nagaoka, T.; et al. In vivo action of novel alkyl methyl quinolone alkaloids against Helicobacter pylori. J. Antimicrob. Chemother. 2002, 50, 547-552. (Pubitemid 35214795)
82. Tominaga, K.; Higuchi, K.; Hamasaki, N.; Tanigawa, T.; Sasaki, E.; Watanabe, T.; Fujiwara, Y.; Oshitani, N.; Arakawa, T.; Ishii, E.; et al. Antibacterial activity of a Chinese herb medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori. Nippon. Rinsho. 2005, 63, 592-599.
83. Chiou, W.F.; Ko, H.C.; Wei, B.L. Evodia rutaecarpa and three major alkaloids abrogate influenza A virus (H1N1)-induced chemokines production and cell migration. Evid. Based Complement. Alternat. Med. 2011, 2011, 750513.
84. Caterina, M.; Julius, D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu. Rev. Neurosci. 2001, 24, 487-517. (Pubitemid 32695237)
85. Pearce, L.V.; Petukhov, P.A.; Szabo, T.; Kedei, N.; Bizik, F.; Kozikowski, A.P.; Blumberg, P.M. Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org. Biomol. Chem. 2004, 2, 2281-2286.
86. Peng, L.; Li, Y.J. The vanilloid receptor TRPV-1: Role in cardiovascular and gastrointestinal protection. Eur. J. Pharmacol. 2010, 627, 1-7.
87. Matsuda, H.; Wu, T.X.; Tanaka, T.; Linuma, M.; Kubo, M. Antinociceptive activities of 70% methanol extract of Evodiae Fructus (fruit of Evodia rutaecarpavar. bodinieri) and its alkaloidal components. Biol. Pharm. Bull. 1997, 20, 243-248. (Pubitemid 27148972)
88. Kano, Y.; Zong, Q.N.; Komatsu, K. Pharmacological properties of galenical preparation, XIV. Body temperature retaining effect of the Chinese traditional medicine, "goshuyu-to" and component crude drugs. Chem. Pharm. Bull. (Tokyo) 1991, 39, 690-692.
89. Tsai, T.H.; Lee, T.F.; Chen, C.F.; Wang, L.C. Thermoregulatory effects of alkaloids isolated from Wu-Chu-Yu in afebrile and febrile rats. Pharmacol. Biochem. Behav. 1995, 50, 293-298.
90. Lin, H.; Tsai, S.C.; Chen, J.J.; Chiao, Y.C.; Wang, S.W.; Wang, G.J.; Chen, C.F.; Wang, P.S. Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 1999, 48, 1532-1535.
91. Yoshizumi, M.; Houchi, H.; Ishimura, Y.; Hirose, M.; Kitagawa, T.; Tsuchiya, K.; Minakuchi, K.; Tamaki, T. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J. Med. Invest. 1997, 44, 79-82. (Pubitemid 127495237)
92. Yu, P.L.; Chao, H.L.; Wang, S.W.; Wang, P.S. Effects of evodiamine and rutaecarpine on the secretion of corticosterone by zona fasciculata-reticularis cells in male rats. J. Cell. Biochem. 2009, 108, 469-475.
93. Yamahara, J.; Yamada, T.; Kitani, T.; Naitoh, Y.; Fujimura, H. Antianoxic action of evodiamine, an alkaloid in Evodia rutaecarpa fruit. J. Ethnopharmacol. 1989, 27, 185-192. (Pubitemid 20018073)
94. Shin, Y.W.; Bae, E.A.; Cai, X.F.; Lee, J.J.; Kim, D.H. In vitro and in vivo antiallergic effects on the fruits of Evodia rutaecarpa and its constituents. Biol. Pharm. Bull. 2007, 30, 197-199. (Pubitemid 46066347)
95. Hu, Y.; Ehli, E.A.; Hudziak, J.J.; Davies, G.E. Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region. Pharmacogenomics J. 2012, 12, 372-378.
96. Kobayashi, Y.; Nakano, Y.; Hoshikuma, K.; Yokoo, Y.; Kamiya, T. The bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of Evodia rutaecarpa, on guinea-pig isolated bronchus: Possible involvement on vanilloid receptors. Planta Med. 2000, 66, 526-530. (Pubitemid 30627540)
97. Guerrant, W.; Patil, V.; Canzoneri, J.C.; Oyelere, A.K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem. 2012, 55, 1465-1477.
98. Wei, J.; Ching, L.C.; Zhao, J.F.; Shyue, S.K.; Lee, H.F.; Kou, Y.R.; Lee, T.S. Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis. Acta Physiol. (Oxf.) 2013, 207, 299-307.
99. Devesa, I.; Planells-Cases, R.; Fernández-Ballester, G.; González-Ros, J.M.; Ferrer-Montiel, A.; Fernández-Carvajal, A. Role of the transient receptor potential vanilloid 1 in inflammation and sepsis. J. Inflamm. Res. 2011, 4, 67-81.
100. Wanner, S.P.; Garami, A.; Pakai, E.; Oliveira, D.L.; Gavva, N.R.; Coimbra, C.C.; Romanovsky, A.A. Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. Cell Cycle 2012, 11, 343-349.
101. Palazzo, E.; Luongo, L.; de Novellis, V.; Rossi, F.; Marabese, I.; Maione, S. Transient receptor potential vanilloid type 1 and pain development. Curr. Opin. Pharmacol. 2012, 12, 9-17.
102. Birerdinc, A.; Jarrar, M.; Stotish, T.; Randhawa, M.; Baranova, A. Manipulating molecular switches in brown adipocytes and their precursors: A therapeutic potential. Prog. Lipid Res. 2012, 52, 51-61.
103. Luo, Z.; Ma, L.; Zhao, Z.; He, H.; Yang, D.; Feng, X.; Ma, S.; Chen, X.; Zhu, T.; Cao, T.; et al. TRPV1 activation improves exercise endurance and energy metabolism through PGC-1α upregulation in mice. Cell Res. 2012, 22, 551-564.
104. Mori, F.; Ribolsi, M.; Kusayanagi, H.; Monteleone, F.; Mantovani, V.; Buttari, F.; Marasco, E.; Bernardi, G.; Maccarrone, M.; Centonze, D. TRPV1 channels regulate cortical excitability in humans. J. Neurosci. 2012, 32, 873-879.
105. Lim, K.M.; Park, Y.H. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch. Pharm. Res. 2012, 35, 393-396.
106. Santoni, G.; Caprodossi, S.; Farfariello, V.; Liberati, S.; Gismondi, A.; Amantini, C. Antioncogenic effects of transient receptor potential vanilloid 1 in the progression of transitional urothelial cancer of human bladder. ISRN Urol. 2012, 2012, 458238.
107. Wang, Z.; Sun, L.; Yu, H.; Zhang, Y.; Gong, W.; Jin, H.; Zhang, L.; Liang, H. Binding mode prediction of evodiamine within vanilloid receptor TRPV1. Int. J. Mol. Sci. 2012, 13, 8958-8969.
108. Giliarov, D.A.; Shkundina, I.S. DNA-topoisomerases and their functions in cell. Mol. Biol. (Mosk.) 2012, 46, 52-63.
109. Thai, K.M.; Bui, Q.H.; Tran, T.D.; Huynh, T.N. QSAR modeling on benzo[c]phenanthridine analogues as topoisomerase I inhibitors and anti-cancer agents. Molecules 2012, 17, 5690-5712.
110. Karki, R.; Thapa, P.; Yoo, H.Y.; Kadayat, T.M.; Park, P.H.; Na, Y.; Lee, E.; Jeon, K.H.; Cho, W.J.; Choi, H.; et al. Dihydroxylated 2,4,6-triphenyl pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Eur. J. Med. Chem. 2012, 49, 219-228.
111. Lee, C.H.; Hsieh, M.Y.; Hsin, L.W.; Chen, H.C.; Lo, S.C.; Fan, J.R.; Chen, W.R.; Chen, H.W.; Chan, N.L.; Li, T.K. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles. Biochem. Pharmacol. 2012, 83, 1208-1216.
112. Sanyal, G.; Doig, P. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin. Drug Discov. 2012, 7, 327-339.
113. Hiltensperger, G.; Jones, N.G.; Niedermeier, S.; Stich, A.; Kaiser, M.; Jung, J.; Puhl, S.; Damme, A.; Braunschweig, H.; Meinel, L.; et al. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei. J. Med. Chem. 2012, 55, 2538-2548.
114. Martin, E.; Thougaard, A.V.; Grauslund, M.; Jensen, P.B.; Bjorkling, F.; Hasinoff, B.B.; Tjørnelund, J.; Sehested, M.; Jensen, L.H. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009, 255, 72-79.
115. Gupta, K.P.; Swain, U.; Rao, K.S.; Kondapi, A.K. Topoisomerase IIβ regulates base excision repair capacity of neurons. Mech. Ageing Dev. 2012, 133, 203-213.
116. Burbach, K.M.; Poland, A.; Bradfield, C.A. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. USA 1992, 89, 8185-8189.
117. Perdew, G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J. Biol. Chem. 1988, 263, 13802-13805.
118. Kazlauskas, A.; Poellinger, L.; Pongratz, I. Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J. Biol. Chem. 1999, 274, 13519-13524.
119. Meyer, B.K.; Pray-Grant, M.G.; Vanden Heuvel, J.P.; Perdew, G.H. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol. Cell. Biol. 1998, 18, 978-988. (Pubitemid 28063432)
120. Pollenz, R.S.; Barbour, E.R. Analysis of the complex relationship between nuclear export and aryl hydrocarbon receptor-mediated gene regulation. Mol. Cell. Biol. 2000, 20, 6095-6104. (Pubitemid 30613057)
121. Hoffman, E.C.; Reyes, H.; Chu, F.F.; Sander, F.; Conley, L.H.; Brooks, B.A.; Hankinson, O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991, 252, 954-958. (Pubitemid 21917012)
122. Reyes, H.; Reisz-Porszasz, S.; Hankinson, O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992, 256, 1193-1195.
123. Tijet, N.; Boutros, P.C.; Moffat, I.D.; Okey, A.B.; Tuomisto, J.; Pohjanvirta, R. Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. Mol. Pharmacol. 2006, 69, 140-153. (Pubitemid 43048901)
124. Israel, D.I.; Whitlock, J.P. Induction of mRNA specific for cytochrome P1-450 in wild type and variant mouse hepatoma cells. J. Biol. Chem. 1983, 258, 10390-10394. (Pubitemid 14241199)
125. Harrigan, J.A.; Vezina, C.M.; McGarrigle, B.P.; Ersing, N.; Box, H.C.; Maccubbin, A.E.; Olson, J.R. DNA adduct formation in precision-cut rat liver and lung slices exposed to benzo[a]pyrene. Toxicol. Sci. 2004, 77, 307-314. (Pubitemid 38262604)
126. Mezrich, J.D.; Nguyen, L.P.; Kennedy, G.; Nukaya, M.; Fechner, J.H.; Zhang, X.; Xing, Y.; Bradfield, C.A. SU5416, a VEGF receptor inhibitor and ligand of the AhR, represents a new alternative for immunomodulation. PLoS One 2012, 7, e44547.
127. Lee, C.; Riddick, D.S. Aryl hydrocarbon receptor-dependence of dioxin's effects on constitutive mouse hepatic cytochromes P450 and growth hormone signaling components. Can. J. Physiol. Pharmacol. 2012, 90, 1354-1363.
128. O'Donnell, E.F.; Kopparapu, P.R.; Koch, D.C.; Jang, H.S.; Phillips, J.L.; Tanguay, R.L.; Kerkvliet, N.I.; Kolluri, S.K. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One 2012, 7, e40926.
129. Platten, M.; Litzenburger, U.; Wick, W. The aryl hydrocarbon receptor in tumor immunity. Oncoimmunology 2012, 1, 396-397.
130. Monteleone, I.; Rizzo, A.; Sarra, M.; Sica, G.; Sileri, P.; Biancone, L.; MacDonald, T.T.; Pallone, F.; Monteleone, G. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011, 141, 237-248.
131. Yu, H.; Tu,Y.; Zhang, C.; Fan, X.; Wang, X.; Wang, Z.; Liang, H. Evodiamine as a novel antagonist of aryl hydrocarbon receptor. Biochem. Biophys. Res. Commun. 2010, 402, 94-98.
132. Xu, H.; Zhang, T.; Yang, H.; Xiao, X.; Bian, Y.; Si, D.; Liu, C. Preparation of evodiamine solid dispersions and its pharmacokinetics. Indian J. Pharm. Sci. 2011, 73, 276-281.
133. Tan, Q.; Liu, S.; Chen, X.; Wu, M.; Wang, H.; Yin, H.; He, D.; Xiong, H.; Zhang, J. Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech. 2012, 13, 534-547.
134. Komatsu, K.; Wakame, K.; Kano, Y. Pharmacological properties of galenical preparation. XVI. Pharmacokinetics of evodiamine and the metabolite in rats. Biol. Pharm. Bull. 1993, 16, 935-938. (Pubitemid 23329810)
135. Jeng, K.F.; Lin, Y.H.; Lin, L.C.; Chou, C.J.; Tsai, T.H.; Chen, C.F. High-performance liquid chromatographic determination of evodiamine in rat plasma: Application to pharmacokinetic studies. J. Chromatogr. B Biomed. Appl. 1995, 668, 343-345.
136. Lin, C.; Pan, X.; Li, W.; Ma, J.; Pan, J.; Cai, J.; Wang, X.; Lin, G. Simultaneous determination of evodiamine and rutecarpine in rabbit plasma by LC-ESI-MS and its application to pharmacokinetics. Pharmazie 2011, 66, 920-923.